Group 1 - The Hang Seng Index fell by 0.65%, down 171 points, closing at 26,312 points, while the Hang Seng Tech Index dropped by 1.04% [1] - Morgan Stanley upgraded the rating for China's wind power industry, suggesting a potential recovery following anti-involution efforts, leading to a rise in wind power stocks such as Goldwind Technology, which increased by 4.6% [1] - Domestic property stocks surged as cities in China optimized real estate policies to stimulate housing demand, with Longfor Group rising by 2.3%, Vanke Enterprises by 2.42%, and Country Garden by 3.5% [1] Group 2 - Huahong Semiconductor reached a new high with a 4.8% increase, following a recent announcement of a restructuring with Huali Microelectronics, and Goldman Sachs noted that the company is negotiating price increases with clients [1] - NetDragon surged over 13% as several of its games are set to launch overseas in the second half of the year, with core IP optimization expected to drive growth [1] Group 3 - Boleton saw a rise of over 20% after signing a strategic cooperation agreement with a mining construction group to advance intelligent development in mine transportation [2] - Lakai Pharmaceuticals increased by over 9% after completing a placement that raised approximately HKD 577 million, intended for the development of its ActRII product portfolio [2] - XPeng Motors rose by over 6% after announcing its entry into five European countries, with the first batch of new cars rolling off the production line at its Austrian factory [2] Group 4 - Xiaomi Group fell by over 5% following the official release of its 17 series smartphones, starting at a price of HKD 4,499 [3] Group 5 - China Everbright Holdings retreated by over 13% after a cumulative increase of over 37% in the previous two trading days [4] - The MicroPort group saw declines across the board, with MicroPort Medical dropping 6.8% due to a major shareholder's discounted sell-off, totaling over HKD 1.1 billion [4]

Core Viewpoint - 来凯医药-B (02105) has seen a significant stock price increase following the announcement of a successful placement of 36 million shares at HKD 16.30 per share, raising approximately HKD 577 million for research and development purposes related to its ActRII product portfolio [1] Group 1: Financial Performance - The stock price rose over 8% to HKD 13.9, with a trading volume of HKD 34.24 million [1] - The net proceeds from the share placement are intended for R&D expenditures for the ActRII product portfolio, ongoing preclinical candidate drug development, and general corporate purposes [1] Group 2: Product Development - The ActRII pathway is identified as a key muscle regulation pathway, attracting interest from multiple multinational pharmaceutical companies [1] - The company has three muscle enhancement products centered around the ActRII pathway, with LAE102 having completed the SAD study and currently undergoing MAD studies [1] - A clinical collaboration agreement with Eli Lilly for LAE102 is set for November 2024, where Eli Lilly will conduct Phase I clinical trials in the U.S. and cover related costs, while the company retains global rights to LAE102 [1] - The company plans to submit clinical trial applications for LAE103 and LAE123 in Q2 2025 and Q3 2025, respectively [1]

Core Viewpoint - 来凯医药-B (02105) has seen a significant stock price increase of over 8% following the announcement of a successful placement of 36 million shares at HKD 16.30 each, raising approximately HKD 577 million for R&D and general corporate purposes [1] Group 1: Financial Details - The company completed the issuance of 36 million placement shares at a price of HKD 16.30 per share, resulting in net proceeds of about HKD 577 million [1] - The funds will be allocated for the R&D expenses of the ActRII product portfolio, ongoing preclinical candidate drug development, and general corporate purposes [1] Group 2: Product Development - The ActRII pathway is a key area for muscle regulation, attracting interest from multiple multinational pharmaceutical companies [1] - The company is developing three muscle-enhancing products around the ActRII pathway, with LAE102 having completed SAD studies and currently undergoing MAD studies [1] - A clinical collaboration agreement with Eli Lilly for LAE102 is set for November 2024, where Eli Lilly will conduct Phase I clinical trials in the U.S. and cover related costs, while the company retains global rights [1] - The company plans to submit clinical trial applications for LAE103 and LAE123 in Q2 2025 and Q3 2025, respectively [1]